Last reviewed · How we verify
Amisulpride IV
Dopamine D2/D3 receptor antagonist
Dopamine D2/D3 receptor antagonist Used for Schizophrenia.
At a glance
| Generic name | Amisulpride IV |
|---|---|
| Sponsor | Acacia Pharma Ltd |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2/D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 1 |
Mechanism of action
Amisulpride acts as a selective antagonist of dopamine D2 and D3 receptors, which are involved in the regulation of motor function and the modulation of the dopaminergic system.
Approved indications
- Schizophrenia
Common side effects
- Akathisia
- Dyskinesia
- Somnolence
Key clinical trials
- Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings (EARLY_PHASE1)
- Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients (PHASE2, PHASE3)
- Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery (PHASE2)
- A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population (PHASE3)
- A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV. (PHASE3)
- Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment
- PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment (PHASE1)
- Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |